Results 181 to 190 of about 3,191,959 (309)

Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.

PURPOSE: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts.
Quigley, DA, Sjöström, M, Feng, E, Lundberg, A, Rydzewski, NR, Helzer, KT, Aggarwal, R, Zhang, M, Zhao, SG, Bootsma, M, Small, EJ, Lang, JM   +11 more
core   +1 more source

Extracellular Vesicle‐Transferred ATP‐Citrate Lyase Induces Monocyte Differentiation Toward Tumor‐Associated Macrophages and Fuels Hepatocellular Carcinoma Progression

Advanced Science, EarlyView.
Hepatocellular carcinoma (HCC)‐derived extracellular vesicles (EVs) enrich the metabolic enzyme ATP‐citrate lyase (ACLY). EV‐transferred ACLY enhances palmitate biosynthesis, increases the S‐palmitoylation and stability of multiple immune checkpoint proteins, augments the cellular immunosuppressive activity, and ultimately accelerates the malignant ...
Zhijun Liu, Haihong Lai, Qing Yang, Chaoyue Zhang, Bin Jia, Qiyi Chen, Yuling Deng, Fen Cao, Yuyu You, Zhe Li, Dongming Kuang, Bo Li   +11 more
wiley   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

Comprehensive Bioinformatic Analysis of TONSL Expression in Pan-Cancer. [PDF]

Cancer Rep (Hoboken)
Yang Y, Zhou B.
europepmc   +1 more source

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

Advanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi   +13 more
wiley   +1 more source

The Journal of Obstetrics and Gynaecology – a new era

Journal of Obstetrics and Gynaecology, 2023
Ayman A. A. Ewies
doaj   +1 more source

A pan-cancer analysis of TMEM132A in human tumors. [PDF]

Discov Oncol
Chu T, Lei C, Zhang X, Wang Y, Gao M.
europepmc   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Pan-cancer ex vivo target evaluation of phosphodiesterase 3 A (PDE3A). [PDF]

J Mol Med (Berl)
Rice K, Lehtinen N, Välimäki E, Suhonen J, Taimen P, Kettunen K, Ventelä S, Kononen J, Sihto H, Rantala JK.   +9 more
europepmc   +1 more source

Adiposity Status Close to Diagnosis and Its Association with Prostate Cancer Survival in the UK Biobank.

UNLABELLED: Substantial evidence links higher adiposity to prostate cancer development. The relationship between adiposity and outcomes after a prostate cancer diagnosis, however, is unclear.
Berrington de González, A, Heath, AK, Cariolou, M, Christakoudi, S, Chan, DSM, Muller, DC, Tsilidis, KK, Gunter, MJ   +7 more
core   +1 more source